Parkinsonism & Related Disorders

Article	Citations
Altered glymphatic system in idiopathic normal pressure hydrocephalus	95
Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics	81
Linear predictive coding distinguishes spectral EEG features of Parkinson's disease	65
Predictors of COVID-19 outcome in Parkinson's disease	61
Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging	60
Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease	57
Unmet needs in Parkinson disease: Motor and non-motor	55
Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features	54
Progressive supranuclear palsy: Advances in diagnosis and management	54
Gut microbiome in Parkinson's disease: New insights from meta-analysis	52
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study	52
Rapid worsening in Parkinson's disease may hide COVID-19 infection	46
Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression	45
The changes of exercise pattern and clinical symptoms in patients with Parkinson's disease in the era of COVID-19 pandemic	44
Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease	40
COVID-19 in Parkinson's disease: Report on prevalence and outcome	40
Machine learning-assisted neurotoxicity prediction in human midbrain organoids	39
Clinical implications of gastric complications on levodopa treatment in Parkinson's disease	39
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study	38
Cerebral small vessel disease may worsen motor function, cognition, and mood in Parkinson's disease	37
The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension	37
Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson's disease	37
Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study	36
Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin	35
MRI biomarkers of motor and non-motor symptoms in Parkinson's disease	33

Increased diagnostic yield in complex dystonia through exome sequencing	32
Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study	31
Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson’s disease	31
Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial	30
How do adenosine A2A receptors regulate motor function?	30
Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations	30
The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant	30
No biallelic intronic AAGGG repeat expansion in RFC1 was found in patients with late-onset ataxia and MSA	29
Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy	29
A physical therapy programme for functional motor symptoms: A telemedicine pilot study	29
Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial	28
Diagnostic accuracy of the appearance of Nigrosome-1 on magnetic resonance imaging in Parkinson's disease: A systematic review and meta-analysis	28
The use of wearable/portable digital sensors in Huntington's disease: A systematic review	28
Life expectancy of parkinsonism patients in the general population	28
Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis	28
Utility of quantitative EEG in early Lewy body disease	27
Impact of home confinement during COVID-19 pandemic on Parkinson's disease	27
Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review	27
Effects of cerebellar transcranial magnetic stimulation on ataxias: A randomized trial	27
Parkinson's disease and skin	26
Tau and MAPT genetics in tauopathies and synucleinopathies	26
Moving towards home-based community-centred integrated care in Parkinson's disease	26
Prediabetes, type 2 diabetes mellitus and risk of Parkinson’s disease: A population-based cohort study	26
Progressive and accelerated weight and body fat loss in Parkinson's disease: A three-year prospective longitudinal study	26
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study	26
Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?	26
Plasma NfL, clinical subtypes and motor progression in Parkinson's disease	26
New generation genetic testing entering the clinic	25
Rate of progression from mild cognitive impairment to dementia in an essential tremor cohort: A prospective, longitudinal study	25
Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder – A PET study	25
The late stage of Parkinson's –results of a large multinational study on motor and non-motor complications	25
Predicting Parkinson's disease using gradient boosting decision tree models with electroencephalography signals	25
Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance	25
Features of “ET plus” correlate with age and tremor duration: “ET plus” may be a disease stage rather than a subtype of essential tremor	24
Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study	24
Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel	24
Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study	24
Closed-loop programming using external responses for deep brain stimulation in Parkinson's disease	23
Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications	23
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis	23
Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic	23
High-frequency repetitive transcranial magnetic stimulation over the primary motor cortex relieves musculoskeletal pain in patients with Parkinson's disease: A randomized controlled trial	23
Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism	22
Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment	22
The psychological impact of COVID-19 among a sample of Italian patients with functional neurological disorders: A preliminary study	22
A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study	22
Long-term effect of bilateral STN-DBS on non-motor symptoms in Parkinson's disease: A four-year observational, prospective study	21
Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?	21
Use of machine learning method on automatic classification of motor subtype of Parkinson's disease based on multilevel indices of rs-fMRI	21
Comparison of 123I-MIBG scintigraphy and phosphorylated α-synuclein skin deposits in synucleinopathies	21

Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study	21
E-Rehabilitation: One solution for patients with Parkinson's disease in COVID-19 era	21
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques	21
Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis	21
Plasma immune markers in an idiopathic REM sleep behavior disorder cohort	21
Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ	20
Novel and reported variants in Parkinson's disease genes confer high disease burden among Indians	20
Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review	20
Movement disorders induced by psychiatric drugs that do not block dopamine receptors	20
Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis	20
Diagnostic criteria for blepharospasm: A multicenter international study	20
Art therapy for Parkinson's disease	20
Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression	19
Peripheral insulin and amylin levels in Parkinson's disease	19
Probiotics for constipation and gut microbiota in Parkinson's disease	19
Subjective cognitive Complaints in early Parkinson's disease patients with normal cognition are associated with affective symptoms	19
Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease	19
Geospatial analysis of individual-based Parkinson's disease data supports a link with air pollution: A case-control study	18
Digital phenotyping in Parkinson's disease: Empowering neurologists for measurement-based care	18
The diagnostic value of clinical neurophysiology in hyperkinetic movement disorders: A systematic review	18
The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study	18
The inconsistency and instability of Parkinson's disease motor subtypes	18
Telemedicine and Deep brain stimulation - Current practices and recommendations	18
Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD)	18
Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis	18
Trends of inpatient palliative care use among hospitalized patients with Parkinson's disease	17
A pilot to assess target engagement of terazosin in Parkinson's disease	17
Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers	17
Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?	17
Parkinson's disease motor subtype changes during 20 years of follow-up	17
Social cognitive impairment in early Parkinson's disease: A novel “mild impairment”?	17
The presence of a caregiver is associated with patient outcomes in patients with Parkinson's disease and atypical parkinsonisms	17
Oropharyngeal freezing and its relation to dysphagia – An analogy to freezing of gait	17
The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3	16
Increased on-state cortico-mesencephalic functional connectivity in Parkinson disease with freezing of gait	16
Quantitative assessment of posture in healthy controls and patients with Parkinson's disease	16
Relating Parkinson freezing and balance domains: A structural equation modeling approach	16
Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data	16
Co-occurring WARS2 and CHRNA6 mutations in a child with a severe form of infantile parkinsonism	16
Impaired metabolic brain networks associated with neurotransmission systems in the α-synuclein spectrum	16
Association of PSP phenotypes with survival: A brain-bank study	16
SLC25A46 mutations in patients with Parkinson's Disease and optic atrophy	16
Anxiety in Parkinson's disease is associated with changes in the brain fear circuit	16
Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive decline	16
Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism	15
FIG4 mutations leading to parkinsonism and a phenotypical continuum between CMT4J and Yunis Varón syndrome	15
Parkinson's disease motor subtypes and bilateral GPi deep brain stimulation: One-year outcomes	15
A validated measure of rigidity in Parkinson's disease using alternating finger tapping on an engineered keyboard	15
Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease	15
Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?	15
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability	15
Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients	15
Functional movement disorder comorbidity in Parkinson's disease: Unraveling the web	15
The commercial genetic testing landscape for Parkinson's disease	15
Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?	15
Cerebello-basal ganglia connectivity fingerprints related to motor/cognitive performance in Parkinson's disease	15
Scientific impact of movement disorders research from Southeast Asia: A bibliometric analysis	15
Clinically relevant copy-number variants in exome sequencing data of patients with dystonia	15
Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder	14
Voice characteristics from isolated rapid eye movement sleep behavior disorder to early Parkinson's disease	14
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease	14
Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease	14
Low-frequency oscillation suppression in dystonia: Implications for adaptive deep brain stimulation	14
Prefrontal network dysfunctions in rapid eye movement sleep behavior disorder	14
Multidisciplinary inpatient rehabilitation for Functional Movement Disorders: A prospective study with long term follow up	14
Dual-task clinical and functional MRI correlates in Parkinson's disease with postural instability and gait disorders	14
Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis	14
Can AI make people happy? The effect of AI-based chatbot on smile and speech in Parkinson's disease	14
Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view	14
Neuropathological findings in PINK1-associated Parkinson's disease	14
Bilateral pallidal stimulation improves cervical dystonia for more than a decade	14
Automated assessment of the substantia nigra on susceptibility map-weighted imaging using deep convolutional neural networks for diagnosis of Idiopathic Parkinson's disease	14
Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [18F]-FEOBV	14
Effects of working memory training in patients with Parkinson's disease without cognitive impairment: A randomized controlled trial	14
Consistent skin α-synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up study	14
In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study	14
Determining an efficient deep brain stimulation target in essential tremor - Cohort study and review of the literature	13
WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia	13
Mind the gap: Inequalities in mental health care and lack of social support in Parkinson disease	13
Motor and non-motor subtypes of cervical dystonia	13

MSA: From basic mechanisms to experimental therapeutics	13
Classification and staging of Parkinson's disease using video-based eye tracking	13
Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease	13
Risk of Parkinson's disease in patients with hypothyroidism: A nationwide population-based cohort study	13
Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis	13
Multimodal assessment of nigrosomal degeneration in Parkinson's disease	13
Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations	13
Parkinsonism in children: Clinical classification and etiological spectrum	13
Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease	13
Exploring the clinical meaningfulness of the Scale for the Assessment and Rating of Ataxia: A comparison of patient and physician perspectives at the item level	13
Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease	13
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity	13
A novel mutation in PSEN1 (p.Arg41Ser) in an Argentinian woman with early onset Parkinsonism	13
Hippocampal impairment in patients with Essential Tremor	13
IRF2BPL mutation causes nigrostriatal degeneration presenting with dystonia, spasticity and keratoconus	13
Isolated and combined genetic tremor syndromes: a critical appraisal based on the 2018 MDS criteria	13
Apolipoprotein E ε4 genotype and risk of freezing of gait in Parkinson's disease	13
The cerebellum in idiopathic cervical dystonia: A specific pattern of structural abnormalities?	12
Clinical patterns of gait freezing in Parkinson's disease and their response to interventions: An observer-blinded study	12
Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease	12
GBA variation and susceptibility to multiple system atrophy	12
Vascular, flow and perfusion abnormalities in Parkinson's disease	12
Drooling rating scales in Parkinson's disease: A systematic review	12
Predictors of general and health-related quality of life in Parkinson's disease and related disorders including caregiver perspectives	12
Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach	12
Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders	12
White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's disease	12
Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank	12
Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease	12
Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up	12
Basal ganglia and cerebellar circuits have distinct roles in blepharospasm	12
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience	12
Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again	12
Toll-like receptor 4 deficiency facilitates α-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease	12
Impulsive and compulsive behaviors in Parkinson's disease: Impact on quality of and satisfaction with life, and caregiver burden	12
Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions	12
Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and “OFF” episodes	12
Effect of deep brain stimulation on caregivers of patients with Parkinson's disease: A systematic review	12
PINK1 p.Leu347Pro mutations in Malays: Prevalence and illustrative cases	12
Neurogenic orthostatic hypotension in early stage Parkinson's disease: New insights from the first 105 patients of the BoProPark study	12
Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany	12
A randomised double-blind controlled study of Deep Brain Stimulation for dystonia in STN or GPi – A long term follow-up after up to 15 years	12
Clarification of undiagnosed ataxia using whole-exome sequencing with clinical implications	12
Relationship between risk and protective factors and clinical features of Parkinson's disease	12
Patterns of diffusion kurtosis changes in Parkinson's disease subtypes	11
α and θ oscillations in the subthalamic nucleus are potential biomarkers for Parkinson's disease with depressive symptoms	11
Predictors of fatigue severity in early, de novo Parkinson disease patients: A 1-year longitudinal study	11
No enhanced (p-) α-synuclein deposition in gastrointestinal tissue of Parkinson's disease patients	11
The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease	11
Ataxia and tolerance after thalamic deep brain stimulation for essential tremor	11
Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia	11
Rest tremor correlates with reduced contralateral striatal dopamine transporter binding in Parkinson's disease	11
Correlations between retinal nerve fiber layer thickness and cognitive progression in Parkinson's disease: A longitudinal study	11
Diagnostic potential of automated tractography in progressive supranuclear palsy variants	11
The faecal metabolome and mycobiome in Parkinson's disease	11
High intensity aerobic exercise improves bimanual coordination of grasping forces in Parkinson's disease	11
Effect of eight-week online cognitive training in Parkinson's disease: A double-blind, randomized, controlled trial	11
Fatigue in hypokinetic, hyperkinetic, and functional movement disorders	11
Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems	11
Constipation distinguishes different clinical-biochemical patterns in de novo Parkinson's disease	11
The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation	11
Motor outcomes and adverse effects of deep brain stimulation for dystonic tremor: A systematic review	11
BDNF levels and nigrostriatal degeneration in “drug naïve” Parkinson's disease patients. An “in vivo” study using I-123-FP-CIT SPECT	11
Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy	11
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors	11
Altered gut microbiota in Parkinson's disease patients with motor complications	10
Paired inhibitory stimulation and gait training modulates supplemental motor area connectivity in freezing of gait	10
Exome-wide rare variant analysis in familial essential tremor	10
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients	10
Increased prevalence of Parkinson's disease in soils with high arsenic levels	10
Movement disorders in systemic autoimmune diseases: Clinical spectrum, ancillary investigations, pathophysiological considerations	10
The neurological and neuropsychiatric spectrum of adults with late-treated phenylketonuria	10
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum	10
The role of disease duration and severity on novel clinical subtypes of Parkinson disease	10
Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease	10
Multimodal dopamine transporter (DAT) imaging and magnetic resonance imaging (MRI) to characterise early Parkinson's disease	10
The global pandemic has permanently changed the state of practice for pre-DBS neuropsychological evaluations	10
Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study	10
Longitudinal evaluation of patients with isolated head tremor	10
Pre-diagnostic presentations of Multiple System Atrophy case control study in a primary care dataset	10
Clinical phenotypes, genotypes and treatment in Chinese dystonia patients with KMT2B variants	10
Objective measurement of limb bradykinesia using a marker-less tracking algorithm with 2D-video in PD patients	10
Autosomal dominant GCH1 mutations causing spastic paraplegia at disease onset	10
Paroxysmal movement disorder with response to carbamazepine in a patient with RHOBTB2 developmental and epileptic encephalopathy	10
A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's disease	10
Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study	10
Higher vitamin B12 level at Parkinson's disease diagnosis is associated with lower risk of future dementia	10
Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias	10
Homozygosity mapping and next generation sequencing for the genetic diagnosis of hereditary ataxia and spastic paraplegia in consanguineous families	10
Initial center of pressure position prior to anticipatory postural adjustments during gait initiation in people with Parkinson's disease with freezing of gait	10
Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease	10
Hippocampal and insula volume in mild cognitive impairment with Lewy bodies	10
Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study	10
Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study	10
Machine learning trained with quantitative susceptibility mapping to detect mild cognitive impairment in Parkinson's disease	10